‫سی ایچ آئی کیو (چِک) کو اپنے مضبوط برانڈ پاور پر بین الاقوامی اعزازات سے نوازا گیا

ژونگشان، چین، 11 جنوری 2023ء/پی آرنیوزوائر/– چین میں بجلی کے گھریلو آلات بنانے والی اعلی پائے کی کمپنی اور اس کے پریمیم برانڈ سی ایچ آئی کیو(چِک) کو حال ہی میں 2022-2023 کے گلوبل ٹی وی برانڈز ٹاپ 10 میں سے ایک کے طور پر نامزد کیا گیا ہے۔ گلوبل ٹاپ برانڈز اتھارٹی، پیشہ ورانہ مہارت، اور اعتبار کا ایک عالمی معیار کا ایونٹ ہے – بین الاقوامی صارفین الیکٹرانکس میں ہال آف آنر 2022-2023 گلوبل ٹاپ برانڈز کے روسٹر اور متعدد سنگل پروڈکٹ ایوارڈز کا اعلان 56 ویں انٹرنیشنل کنزیومر الیکٹرانکس شو (سی ای ایس 2023) میں کیا گیا ، جو عالمی ٹیکنالوجی انڈسٹری کے لئے سرفہرست دس سالانہ ایونٹس میں سے ایک ہے، جو 5 سے 8 جنوری تک لاس ویگاس میں منعقد ہوا تھا۔اس سال کا سی ای ایس ایک وسیع آف لائن بحالی کے آغاز کی نشاندہی کرتا ہے۔

چانگ ہونگ نے گھریلو انٹرنیٹ صارفین کے الیکٹرانکس کی جگہ میں طویل مدتی ترقی کے لئے سی ایچ آئی کیو(چِک) برانڈ تخلیق کیا۔ یہ برانڈ مصنوعات کی ایک وسیع رینج پیش کرتا ہے، بشمول ٹیلی ویژن، ریفریجریٹر، اور ایئر کنڈیشنر۔ چانگ ہونگ صارفین کو سی ایچ آئی کیو(چِک) کے ذریعے زیادہ آرام دہ اور خود ساختہ رہنے کا تجربہ فراہم کرنے کی توقع رکھتا ہے۔

سی ایچ آئی کیو (چِک) نے 2017 کے بعد سے عالمی مارکیٹوں میں مسلسل توسیع کی ہے، جس میں 30 سے زائد ممالک اور 40 سے زائد ملٹی مارکیٹ ای کامرس پلیٹ فارمز بشمول ایمیزون، لازاڈا اور شوپی شامل ہیں۔ 2022-2023 گلوبل ٹی وی برانڈز ٹاپ 10 ایوارڈ کے حصول کے ساتھ اس کی کامیابی کے ثبوت کے طور پر خدمات انجام دے رہا ہے ، سی ایچ آئی کیو (چِک) اپنی طاقت اور بہت سے میڈیا چینلز کی وجہ سے چین سے باہر صارفین کے لئے تیزی سے جانا جاتا ہے جس کے ذریعے برانڈ کو فروغ دیا جاتا ہے ، یہ سب برانڈ کے اثر و رسوخ کو بڑھانے کے لئے کام کرتے ہیں۔

سی ایچ آئی کیو (چِک) کا مقصد ہر شخص کے گھر کو رہنے کی جگہ بنانا ہے جہاں سے وہ ذہین ، مکمل ڈیزائن ، اور جدید مصنوعات کی ایک لائن اپ فراہم کرکے روحانی اطمینان حاصل کرسکتے ہیں جو ان کی زندگی کی اقدار (رنگین ، مشغول ، مثبت اور لطف اندوز ہونے کے ذریعہ) کے ساتھ گونجتے ہیں۔ اس مقصد کے لئے ، سی ایچ آئی کیو (چِک) نے مور پلس (اپنی زندگی سے مزید حاصل کریں) کا خیال تیار کیا ، جس سے ڈیزائن ، تفریح ، تخلیقی ، انتخاب ، اسٹائل ، اور ویلیو کے تصورات کو اپنی طرف متوجہ کرنا ممکن ہے۔

آج ، سی ایچ آئی کیو(چِک) کی مصنوعات کے زمرے ٹی وی ، ریفریجریٹرز اور ایئر کنڈیشنرز سے آگے بڑھ رہے ہیں جس میں واشنگ مشینیں ، مانیٹر اور فلور سویپر شامل ہیں۔ اس کی مصنوعات کی لائن کی مسابقت بھی ایک ہی وقت میں بڑھ رہی ہے۔ اعلی معیار کی مصنوعات برانڈ کی بنیاد ہیں۔ اس بات کو ذہن میں رکھتے ہوئے، سی ایچ آئی کیو (چِک) ذہین اور قابل اعتماد مصنوعات کی فراہمی کے لئے اپنی تکنیکی صلاحیتوں کو بہتر بنانا جاری رکھے گا جو اپنے صارفین کے لئے ڈیجیٹل طور پر اسمارٹ زندگی تخلیق کرتے ہیں۔

Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)

Global Phase 3 INDIGO study will evaluate the efficacy and safety of obexelimab in patients with IgG4-RD, a chronic and serious fibroinflammatory disease typically affecting multiple organs

IgG4-RD is the first of several potential disease indications to be pursued for obexelimab given its unique non-depleting, B-cell inhibition

WALTHAM, Mass., Jan. 11, 2023 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies, today announced that the first patient has been dosed in the INDIGO Phase 3 registrational study of obexelimab. The INDIGO study will evaluate the clinical efficacy and safety of obexelimab treatment in the prevention of IgG4-related disease (IgG4-RD) flare. Obexelimab is a high-affinity bifunctional antibody that inhibits B-cell lineages by simultaneously binding to CD19 and FcƳRIIB, thereby downregulating B-cell activity in patients with autoimmune diseases associated with autoantibodies, such as IgG4-RD.

“IgG4-RD is a chronic and serious fibroinflammatory condition that can affect nearly any organ system and can have a profound impact on many patients, leading to severe organ damage or death,” said Hua Mu, M.D., Ph.D., Chief Executive Officer at Zenas. “There are no currently approved treatments for patients living with IgG4-RD. Based upon the promising data from a Phase 2 study of obexelimab in IgG4-RD patients, we are excited to continue to evaluate the potential of obexelimab in the INDIGO study.”

About the INDIGO Study

The INDIGO study is a global multicenter, randomized, double-blind, placebo-controlled study enrolling up to 200 adults with active IgG4-RD signs/symptoms (i.e., flare) that require steroid therapy. Patients will be randomized in a ratio of 1:1 to receive either obexelimab or placebo, administered as subcutaneous injections.

The primary endpoint of INDIGO is time to first IgG4-RD flare (defined as the reappearance of previous signs/symptoms or appearance of new signs/symptoms of IgG4-RD) that requires initiation of rescue therapy from randomization to Week 52. Safety will be evaluated throughout the study duration.

More information on the INDIGO study (NCT05662241) is available at clinicaltrials.gov.

About Obexelimab

Obexelimab is an investigational Phase 3-stage, novel bifunctional antibody with first-in-class potential that inhibits B-cell lineages that express CD19. Simultaneous binding to CD19 and FcƳRIIB by obexelimab mimics a natural antigen-antibody complex and downregulates B cell activity. In several early-stage clinical studies, 198 subjects were treated with obexelimab. In these clinical studies, the molecule demonstrated effective inhibition of B cell function without depleting the cells and generated an encouraging treatment effect in patients with multiple autoimmune diseases. Zenas acquired exclusive worldwide rights to obexelimab from Xencor, Inc.

About IgG4-RD

IgG4-RD is a chronic and serious fibroinflammatory disease typically affecting multiple organs (e.g., pancreas, liver, kidney, bile duct, salivary and lacrimal glands). Approximately 20,000 people are diagnosed with IgG4-RD in the US, with similar prevalence rates across geographies. Many patients have some degree of irreversible organ damage at the time of diagnosis. Although nearly all patients initially respond to glucocorticoid (GC) therapy, a majority of patients will relapse/flare within a few months of discontinuing treatment, requiring rescue therapy. Chronic GC therapy is also associated with toxicity in many patients.

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients around the world. With clinical development and operations globally, Zenas is advancing a deep and balanced global portfolio of potential first- and best-in-class autoimmune therapeutics in areas of high unmet medical need while meeting the value requirements of the dynamic global healthcare environment. The company’s pipeline continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those living with autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.

Investor and Media Contact:
Joe Farmer, President & COO
Zenas BioPharma
IR@zenasbio.com

GlobeNewswire Distribution ID 8727743

Heirs of Baldia factory fire incident reject insurance pact 

Karachi, January 11, 2023 (PPI-OT):Heirs of Ali Enterprises Baldia factory fire and representatives of labour organisations here Wednesday expresses serious concerns about pact of International Labour Organisation (ILO) with an insurance company regarding compensation money given by a German brand for the heirs, rejecting it by terming it non transparent.

Addressing a joint press conference, the leaders of the Association of Affectees of Baldia factory fire, National Trade Union Federation Pakistan, PILER, Home Based Women Workers Federation, Joint Action Committee, Human Rights Commission of Pakistan and SITE Labour Forum including Muhammad Siddique, Hussina Khan, Nasir Mansoor, Karamat Ali, Asad Iqbal Butt, Zehra Khan, Mahnaz Rahman and Riaz Abbasi said that the ILO took a unilateral decision without taking the real party of Baldia factory fire in confidence. They said that the interests of labours would be safeguarded at all costs.

They said that the general body meeting of Association of the Affectees of Baldia factory fire was held in Karachi on Sunday in which important decisions were taken. It paid rich tributes to Association leader Saeeda Khatoon who died battling cancer. Her struggle was lauded greatly.

They said that the heirs of 260 martyrs of Baldia factory fire and dozens of the injured and their supporter local and international labour organisations after a great struggle inked a deal with German brand KIK that agreed to pay a long term compensation of $5.1million. The representative of KIK and signed the deal in 2016, with workers organisations under ILO, IndustiAll Global and Clean Cloth Campaign and the funds were given to ILO Geneva office.

They said that under this deal an oversight committee was formed at Pakistan level to distribute these funds and take care of the related issues with representation of the government, labour organisations, heirs and factory owners. The heirs demanded that as per the deal the compensation funds should be brought to Pakistan and invested with mutual consultation to ensure lifelong assistance of the heirs and affectees. In this regard the association of the heirs and labourer organisations in consultation with noted Pakistani lawyers shared an investment plan with the ILO, but the ILO didn’t respond.

They said that sadly the ILO while violating the deal and despite repeated demands of the heirs kept the compensation funds for last five years and distributed monthly compensation amongst the heirs through SESSI. Hence, a big chuck of these funds was spent and the heirs and stakeholders were not informed about it. They said that the ILO is responsible for all this.

The speakers said that the ILO didn’t play any role in helping the affectees. It ignored the demands of the heirs and stakeholder labour organisations and took unilateral and non-transparent decisions and implemented them.

They said that the ILO convened a meeting on December 15 when a member of the oversight committee and patron of the association of the affected workers was hospitalised for treatment of cancer, another member Nasir Mansoor was abroad and the third member Karamat Ali was ill. They were requested to postpone the meeting but in vain. In this meeting the ILO ratified a contract with an insurance company, which had already been signed before the meeting without consultation with the stakeholders who were not told about this contract.

The ILO had no right to sign a deal about the funds of the heirs without consultation with them in this non transparent manner. After this non transparent deal some officials of the ILO Karachi office with help of a SESSI employee are harassing the heirs and forcing then sign some documents written in English language. This act has created unrest among the heirs of the martyred workers.

They said that after the international agreement between the German brand and labour organisations, the Sindh government and the Labour Department are the essential parties of the contract and through them the payment of monthly compensation through SESSI was started. However, the labour department failed to play its due role and didn’t take all the members of the oversight committee in confidence.

They said that the contract with the insurance company before the meeting of the oversight committee and without any consultation is the worst example of non-transparency and an attack on the basic and democratic right of the heirs.

They demanded to the ILO should invest the compensation funds after the consultation with the heirs and stakeholder labour organisations.

They asked to summon a meeting of the oversight committee and all documents including that of the deal with the insurance company should be shared with its members.

They demanded that the ILO Karachi office should stop harassing the heirs, otherwise, a protest would be held outside the office.

They asked the SESSI commissioner to start probe against their employ Maroof for forcing the heirs to sign some unknown papers. They asked to hold responsible those officers who caused decrease in the original compensation funds.

They demanded the Compensation Commissioner to decide the gratuity cases of the deceased workers of the West. They asked to ensure EOBI pension to the parents of the martyred workers in the light of the decision of Sindh High Court. They asked to stop the selling of the affected factory and instead erect a symbol there in the memory of the martyred workers.

For more information, contact:
Home Based Women Workers Federation (HBWWF)
726, Mashrique Centre, Block 14, Gulshan-e-Iqbal,
Karachi, Pakistan
Tel: +92-21-37075324
Website: https://hbwwf.org/

Office of Research, Innovation and Commercialization Organized Two Days Hand-on Workshop on SPSS 

Islamabad, January 11, 2023 (PPI-OT):Office of Research, Innovation and Commercialization (ORIC) in collaboration with Dean Faculty of Health and Life Sciences (FHLS) organized “Two-Days Hands-on Workshop on SPSS” on 29th December, 2022 and 05th January, 2023 in Instructions Lab-6, M-Block. The purpose of the workshop was to equip participants with the most updated knowledge about statistical/quantitative analysis using SPSS with practical illustrations.

SPSS is one of the most widely available/powerful statistical software packages that covers a broad range of statistical procedures and allow researcher to summarize data (compute means and standard deviations), determine significant differences between groups (t-tests, analysis of variance), examine relationships among variables (correlation, multiple regression), and graphical presentation of data. Some of the key topics covered in the workshop were:

1. Data Entry: Manually and from Excel

2. Editing and Organizing Datasets

3. Data Transformations

4. Descriptive Statistics

5. Graphical Displays

6. Procedures for Exploring Relationships

7. Simple and Multiple linear Regression Analyses

8. Mediation and Moderation Analyses

The workshop was conducted by Dr. Sohail Rizwan from Fatima Jinnah Women University (FJWU), Rawalpindi. A total of 15 participants including students from Biosciences/Bioinformatics/Microbiology Departments attended the workshop. The response of participants was quite promising and workshop proved to be a great source of hands-on knowledge to the participants.

For more information, contact:
Capital University of Science and Technology (CUST)
Islamabad Expressway, Kahuta Road, Zone-V, Islamabad, Pakistan
UAN: +92-51-111-555-666
Tel: +92-51-4486700-4
Email: info@cust.edu.pk
Website: https://cust.edu.pk

PTI leader Farrukh Habib calls on Chief Minister Punjab Chaudhry Parvez Elahi

Lahore, January 11, 2023 (PPI-OT):Former federal minister and PTI leader Farrukh Habib called on Chief Minister Punjab Chaudhry Parvez Elahi at his office and discussed matters of mutual interest. The CM noted that the alliance with the PTI was getting stronger with every passing moment and added that the designs of the propagandists would be frustrated. Politics is like worshipping but some elements have turned it into a business, he said and added that the nation was watching how deals of conscience were being made.

He asserted that the government was more than determined to counter the unconstitutional tactics of the opposition. PML-N was following the agenda of anarchy while we advanced a goal of public service, he added and maintained that every city has been made part of the development process. No area would be deprived of development, he concluded.

Farrukh Habib said that the PDM-led government has snatched daily food items from the people. The imported government was, now, taxing breathing on the dictates of the IMF, he said and appreciated the steps taken by the Punjab government to provide relief to the common man. Principal Secretary to CM Muhammad Khan Bhatti was also present.

For more information, contact:
Mediacell, Pakistan Muslim League
30-C, Chaudhry Zahoor Elahi Road,
Gulberg-II, Lahore, Pakistan
Tel: +92-42-35878428
Fax: +92-42-35877329
Website: www.pmlmediacell.com

Chief Minister Punjab Chaudhry Parvez Elahi inaugurates construction work of Rs 8. 65 billion new emergency and Trauma Center project of Jinnah Hospital 

Lahore, January 11, 2023 (PPI-OT):Chief Minister Punjab Chaudhry Parvez Elahi inaugurated the construction work of the 256-bedded new emergency and trauma center of Jinnah Hospital by pressing a button on Wednesday. Provincial Specialised Healthcare Minister Dr Yasmin Rashid and Secretary Ahmad Javed Qazi gave a briefing about the Rs. 8. 65 billion project.

In addition to allocating beds for accidents and other emergencies, 24 beds will be allocated for cardiac emergencies, and 48 for surgical and allied emergencies. The trauma center and a new emergency were required to deal with the rush of patients while diagnostic services, including cath lab, pathology, radiology and pharmacy, will also be available in the new emergency, the CM said and mentioned that the lift, ramp, wheelchair, stretcher and other facilities were being provided for the convenience of patients and their attendants.

The seven-storey emergency block and trauma center project would be completed within the stipulated period and all the medicines will be provided free of cost in the emergency, he added and appreciated that Dr Yasmin Rashid and her team were burning the midnight oil to provide quality healthcare facilities to the patients.

Provincial Ministers Mohsin Leghari, Latif Nazar, Principal Secretary to CM Muhammad Khan Bhatti, Finance Secretary Mujahid Sherdil, CEO IDAP, DG Protocol, DGPR Rao Parvez Akhtar, Principal Allama Iqbal Medical College, MS Jinnah Hospital, Chairman BoM Allama Iqbal Medical College, member BoM Barrister Sahibzada Muzaffar, Prof Masood Rashid and others were also present.

For more information, contact:
Mediacell, Pakistan Muslim League
30-C, Chaudhry Zahoor Elahi Road,
Gulberg-II, Lahore, Pakistan
Tel: +92-42-35878428
Fax: +92-42-35877329
Website: www.pmlmediacell.com